Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06454968

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Led by Peking Union Medical College Hospital · Updated on 2024-06-18

45

Participants Needed

1

Research Sites

206 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).

CONDITIONS

Official Title

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 63; 18 years, any gender
  • Histopathologically confirmed B-cell non-Hodgkin lymphoma Marginal Zone Lymphoma (splenic, nodal, or extra-nodal)
  • At least 1 measurable lesion
  • Eligible for treatment by GELF criteria or has disease-related clinical symptoms or organ dysfunction
  • Not suitable for local radiotherapy or disease progressed after local treatment, including Ann Arbor non-continuous Stage II or Stage III-IV non-gastric MALT and nodal MZL, SMZL, or gastric MALT with Lugano Stage II2/IIE/IV
  • ECOG performance status score of 0-2
  • Expected survival time of 3 months or more
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Currently has other malignant tumors
  • Lymphoma involving the central nervous system
  • Allergy to any of the study drugs
  • Active infection or uncontrolled HBV infection (DNA >105/ml), HIV/AIDS, or other severe infections
  • Pregnant or lactating women and women of childbearing age unwilling to use contraception
  • Any other conditions that the investigator considers unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

J

Jiayue Li

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here